Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 6 examiners • 2 of 7 (29%) have an AI response strategy ready • 2 patents granted in the last 365 days
Sana Biotechnology Inc. has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters span 7 distinct examiners and 6 distinct art units, showing a broadly distributed docket with some examiner and art-unit overlap. Portfolio management should therefore combine centralized deadline oversight with response preparation tailored to individual examination assignments.
MOORE, JOHN DAVID is the busiest examiner, with 2 pending actions. That examiner's matters form the most apparent concentration in the supplied data and may benefit from coordinated review of claim scope and recurring technical positions. The remaining assignments require separate attention because their examination contexts are distributed across additional examiners and art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 2 (29%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, JOHN DAVID | 2 | 61.1% | +28.3% |
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
| GRABER, JAMES J | 1 | 46.5% | +57.6% |
| EBBINGHAUS, BRIANA NOEL | 1 | 59.7% | +63.0% |
| PETERS, ALEC JON | 1 | 67.4% | +54.8% |
| MCCORMICK, CATHERINE LYNN | 1 | 52.3% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031771 | HEPATOCYTE-LIKE CELLS | EBBINGHAUS, BRIANA NOEL | 19d overdue |
| 18720534 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | MOORE, JOHN DAVID | — |
| 18682798 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY | MOORE, JOHN DAVID | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031771 | HEPATOCYTE-LIKE CELLS | EBBINGHAUS, BRIANA NOEL | 19d overdue |
| 17637789 | CD24 EXPRESSING CELLS AND USES THEREOF | MCCORMICK, CATHERINE LYNN | 63d |
| 18720534 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | MOORE, JOHN DAVID | — |
| 18682798 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY | MOORE, JOHN DAVID | — |
| 18682778 | INDUCIBLE SYSTEMS FOR ALTERING GENE EXPRESSION IN HYPOIMMUNOGENIC CELLS | BELYAVSKYI, MICHAIL A | — |
| 18682797 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY TO REDUCE INSTANT BLOOD MEDIATED INFLAMMATORY REACTIONS | GRABER, JAMES J | — |
| 18030880 | METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPalpha BLOCKADE AGENT | PETERS, ALEC JON | — |
| Art Unit | Apps |
|---|---|
| 1638 | 3 |
| 1644 | 1 |
| 1631 | 1 |
| 1632 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18720534 | MODIFIED PARAMYXOVIRIDAE FUSION GLYCOPROTEINS | MOORE, JOHN DAVID | 1638 | §103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18682798 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY | MOORE, JOHN DAVID | 1638 | §103§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18682778 | INDUCIBLE SYSTEMS FOR ALTERING GENE EXPRESSION IN HYPOIMMUNOGENIC CELLS | BELYAVSKYI, MICHAIL A | 1644 | §102Other | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18682797 | GENETICALLY MODIFIED CELLS FOR ALLOGENEIC CELL THERAPY TO REDUCE INSTANT BLOOD MEDIATED INFLAMMATORY REACTIONS | GRABER, JAMES J | 1631 | §103§112DP | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18031771 | HEPATOCYTE-LIKE CELLS | EBBINGHAUS, BRIANA NOEL | 1632 | §102§103§112 | Final Rejection | 19d overdue | AI Ready | Apr 13, 2023 |
| 18030880 | METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPalpha BLOCKADE AGENT | PETERS, ALEC JON | 1641 | §112 | Final Rejection | — | Pending | Apr 07, 2023 |
| 17637789 | CD24 EXPRESSING CELLS AND USES THEREOF | MCCORMICK, CATHERINE LYNN | 1638 | §102 | Final Rejection | 63d | AI Ready | Feb 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSana Biotechnology Inc. has 7 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
John David Moore has the most, with 2 of Sana Biotechnology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
